Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241084 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6236104 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL11823195 | 0.79 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6237975 | 0.77 | OPRK1 (0.37) | SMN1; SMN2TSHRALOX5GAA | |
| SCHEMBL6827765 | 0.74 | ALOX5 (0.45) | SMN1; SMN2MAPTALOX5 | |
| SCHEMBL20723862 | 0.74 | MAPT (0.43) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6235316 | 0.73 | ALOX5 (0.38) | ALDH1A1MEN1KMT2ASMN1; SMN2ATM | |
| Urethane SCHEMBL25305538 | 0.73 | ALOX15 (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| Ethyl Acetate SCHEMBL27584643 | 0.72 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL22729195 | 0.72 | ALOX5 (0.43) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | claimed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| CN-100398102-C | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2008-07-02 | — | — | CN | disclosed |
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1681488-A | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1537866-A1 | DRUG FOR KIDNEY FAILURE CONTAINING OXALURIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4708954-A | DIABETES-ORAL ADMINISTRATION | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | OAT, OTC, OGFRL1 | ALDH1A1 325/4885MEN1 4680/4885KMT2A 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.